@article{Spadaro_Scarno_Carboni_Perrotta_Catalano_Lubrano_Valesini_2013, title={Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis}, volume={65}, url={https://www.reumatismo.org/reuma/article/view/reumatismo.2013.134}, DOI={10.4081/reumatismo.2013.134}, abstractNote={In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.}, number={3}, journal={Reumatismo}, author={Spadaro, A. and Scarno, A. and Carboni, A. and Perrotta, F.M. and Catalano, C. and Lubrano, E. and Valesini, G.}, year={2013}, month={Jul.}, pages={134–137} }